On January 6, the net outflow of the pharmaceutical and biological sector exceeded 1.8 billion yuan

【Pharmaceutical Network Pharmaceutical Stock Market】 Data show that on January 6, the main funds net inflow into electrical machinery, chemicals, steel and other sectors, net outflow of pharmaceutical biology, real estate, big finance and other sectors, of which the pharmaceutical and biological sector net outflow of 1.
884 billion
.
From the perspective of individual stocks, as of 14:15 on January 6, Goertek shares were sold more than 700 million yuan, and the net outflow of main funds such as Unigroup Guowei, Annie Shares, and Meiliyun ranked first
.
In the pharmaceutical field, Tongrentang sold a net of 247 million yuan
.
Data show that on January 6, Tongrentang fell by 5% intraday, and as of 14:04, it was reported at 42.
28 yuan, with a transaction of 848 million yuan and a turnover rate of 1.
44%.

In addition, the data shows that Tongrentang was financed to buy 74.
5727 million yuan on January 5, accounting for 28.
09% of the purchase amount on that day, and the current financing balance is 992 million yuan, accounting for 1.
62% of the circulating market value, exceeding the historical 70% decile level
.
In terms of securities financing, Tongrentang repaid 48,600 shares on January 5, and sold 39,200 shares on margin trading, with a selling amount of 1,744,800 yuan based on the closing price of the day, accounting for 0.
33% of the outflow amount on the day; The balance of securities lending was 19.
0626 million, exceeding the historical 80% level and being at a relatively high level
.
According to the data, Tongrentang is mainly engaged in the production and sales of traditional proprietary Chinese medicines, and produces more than 400 specifications of proprietary Chinese medicines all year round, with rich product dosage forms, covering more than 20 product dosage forms
such as pills, powders, wines and capsules, oral liquids, and pills.
At present, Tongrentang Group has gradually formed a "1+N" health industry business layout with pharmaceuticals as the core
.
At present, in the business pattern, five sectors
have been formed, with the pharmaceutical industry as the core and supported by health care, medical pension, commercial retail, and international pharmaceutical.
From the company's main financial indicators in recent years, the operating income and net profit attributable to the parent grew rapidly from 2012 to 2015, with CAGRs of 15.
34% and 18.
89%, respectively, and steadily increased from 2016 to 2018, with CAGRs of 9.
55% and 9.
03%, respectively, affected by quality reform and capacity adjustment in 2019, and decreased in performance in
2020 due to the impact of the epidemic 。 However, in the past two years, the company has deepened the reform of the channel end and focused on the "big variety" strategy, which has achieved initial results, and the operating income and net profit attributable to the parent in 2021 increased by 13.
85% and 19.
01% year-on-year, respectively, and the company's performance is expected to resume rapid growth
in the next few years.
In the first three quarters of 2022, the company achieved operating income of 10.
9 billion yuan, a year-on-year increase of 2.
03%; The net profit was 1.
003 billion yuan, a year-on-year increase of 9.
01%.

From the perspective of the inflow of main funds, as of 14:15 on January 6, BOE A rose, with a net purchase of 550 million yuan of main funds, and Chint Electric, Tongwei Shares, TCL Central and other main funds ranked first
.
In the pharmaceutical field, WuXi AppTec received a net inflow of 241 million yuan, ranking
tenth.
In addition, data shows that as of the close on January 5, 2023, WuXi AppTec closed at 87.
97 yuan, up 6.
5%, with a turnover rate of 1.
67%, a volume of 427,800 lots, and a turnover of 3.
707 billion yuan
.
On January 5, it received a net inflow of main funds of 607 million yuan, accounting for 16.
37% of the total turnover, a net outflow of 316 million yuan, accounting for 8.
51% of the total turnover, and a net outflow of retail funds of 291 million yuan, accounting for 7.
85% of
the total turnover.
On December 16, 2022, WuXi Dekang expressed its belief in pharmaceutical innovation will continue to progress, and the global biomedical industry will be committed to developing more and more effective drugs to meet a large number of unmet clinical needs
.
In the first three quarters of 2022, the company added more than 1,000 new customers and more than 5,900 active customers, and customer demand for the company's services around the world continued to grow
strongly 。 In addition, according to WuXi AppTec's 2022 third quarter report, the company's main revenue in the first three quarters of 2022 was 28.
395 billion yuan, a year-on-year increase of 71.
87%; the net profit attributable to the parent was 7.
378 billion yuan, an increase of 107.
12% year-on-year; Non-net profit was RMB6.
232 billion, up 100.
64% year-on-year; Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.